palonosetron_hydrochloride: profile and news

MGI PHARMA to Present at the 2006 Bank of America Health Care ...  May 11, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - PharmaLive.com (press release),

US FDA Approves Dacogen(TM) (Decitabine) For Injection  May 3, 2006
MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection and Gliadel® Wafer (polifeprosan 20 with carmustine implant) in the United States, and ... - Yahoo! News (press release)

US FDA Approves Dacogen(TM) (Decitabine) for Injection; Dacogen(TM ...  May 3, 2006
MGI PHARMAmarkets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R)Wafer (polifeprosan 20 with carmustine implant) in the United States,and ... - Finanzen.net,

MGI PHARMA Announces Publication of Phase 3 Data for Dacogen ...  Apr 18, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - PharmaLive.com (press release),

MGI PHARMA Reports First Quarter 2006 Financial Results; First ...  Apr 19, 2006
During the first quarter of 2006, US sales of Aloxi(R) (palonosetron hydrochloride) Injection totaled $63.3 million compared to $57.2 million in the first ... - Business Wire (press release),